Literature DB >> 15661554

Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.

David Osoba1, Andrea Bezjak, Michael Brundage, Benny Zee, Dongsheng Tu, Joseph Pater.   

Abstract

Clinicians are being confronted with increasing amounts of health-related quality of life (HRQOL) data. Thus, there is a need for a greater understanding of the analysis and interpretation of HRQOL so that the data can be reported in an appropriate manner. The approach of the Clinical Trials Group of the National Cancer Institute of Canada emphasises the clinical meaning of the results, while avoiding complex statistical modelling. It consists of four steps: calculating the questionnaire completion rates, calculating the baseline scores, determining the individual change in scores over time for the domains specified in the trial hypothesis, and culminates in determining the proportions of patients who have reported clinically meaningful changes in scores since baseline. A rationale supporting each step is given. This approach is presented as a simple and practical aid to the analysis, interpretation and reporting of HRQOL results.

Entities:  

Mesh:

Year:  2005        PMID: 15661554     DOI: 10.1016/j.ejca.2004.10.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  59 in total

1.  Reliability and validity of the Norwegian child and parent versions of the DISABKIDS Chronic Generic Module (DCGM-37) and Diabetes-Specific Module (DSM-10).

Authors:  Dag Helge Frøisland; Trond Markestad; Tore Wentzel-Larsen; Torild Skrivarhaug; Knut Dahl-Jørgensen; Marit Graue
Journal:  Health Qual Life Outcomes       Date:  2012-02-02       Impact factor: 3.186

2.  Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.

Authors:  Lori Brotto; Michael Brundage; Paul Hoskins; Ignace Vergote; Andres Cervantes; Herraez A Casado; A Poveda; Elizabeth Eisenhauer; Dongsheng Tu
Journal:  Support Care Cancer       Date:  2015-08-25       Impact factor: 3.603

3.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

4.  Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.

Authors:  Vikki Ho; Romain Pasquet; Shaman Luo; Gang Chen; Paul Goss; Dongsheng Tu; Philip Lazarus; Harriet Richardson
Journal:  Breast Cancer Res Treat       Date:  2020-08-01       Impact factor: 4.872

5.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

6.  MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.

Authors:  P Grossman; L Kappos; H Gensicke; M D'Souza; D C Mohr; I K Penner; C Steiner
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

7.  Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.

Authors:  Heather-Jane Au; Wolfgang Eiermann; Nicholas J Robert; Tadeusz Pienkowski; John Crown; Miguel Martin; Marek Pawlicki; Arlene Chan; John Mackey; John Glaspy; Tamás Pintér; Mei-Ching Liu; Tommy Fornander; Sandeep Sehdev; Jean-Marc Ferrero; Valerie Bée; Maria J Santana; Dave P Miller; Deepa Lalla; Dennis J Slamon
Journal:  Oncologist       Date:  2013-06-28

8.  Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.

Authors:  Andrea Bezjak; Christopher W Lee; Keyue Ding; Michael Brundage; Timothy Winton; Barbara Graham; Marlo Whitehead; David H Johnson; Robert B Livingston; Lesley Seymour; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

9.  Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program.

Authors:  Lene Kongsgaard Nielsen; Rikke Faebo Larsen; Lene Jarlbaek; Sören Möller; Eva Jespersen
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

10.  Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.

Authors:  Hans Geinitz; Reinhard Thamm; Christian Scholz; Christine Heinrich; Nina Prause; Simone Kerndl; Monika Keller; Raymonde Busch; Michael Molls; Frank B Zimmermann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.